DMD Gene Therapy Candidate SGT-003 Receives Rare Pediatric Disease Designation from FDA.

Published Date: 19 May 2024

Midway through 2024, Solid Biosciences anticipates the first few pediatric Duchenne muscular dystrophy patients enrolled in the phase 1/2 INSPIRE Duchenne trial will provide preliminary safety data on SGT-003.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Boom in ADHD Coaching Has Few Rules

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

4.

Medicaid expansion tied to smaller declines in early-stage cancer detection

5.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot